AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in…
OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the…